Tecentriq extends streak with win in breast cancer trial ; In FDA first, Dermira secures approval for excessive sweating drug; Biopharma embracing real-world evidence, report says; Celgene gets key Phase 3 win with anemia drug
Learn how emerging biotechs are avoiding costly delays and creating efficiencies in their gene therapy trials with coordinated IRB and IBC review.
Read more
Roche claimed Tecentriq's success in IMpassion 130 as the first positive Phase 3 study of an immunotherapy in triple-negative breast cancer. An overall survival benefit, however, has yet to be established.
Learn how cloud computing and similar technologies can adapt to trial volatility, thus enhancing efficiency and saving pharma companies millions of dollars. Download now→
In a further blow, Galapagos' partner AbbVie decided to back out of development of another triple combination study, raising doubts about the smaller biotech's program.
We're excited to announce the launch of our brand new publication: MedTech Dive. Starting July 16, the daily newsletter will chronicle the transformation of medical devices, diagnostics and technologies, and how these changes impact the industry.
Our mission is to provide busy execs like you with an overview of the BioPharma industry in 60 seconds. BioPharma Dive is a product of Industry Dive. View other Industry Dive publications.
This email is optimized for display on mobile phones. BioPharma Dive is a product of Industry Dive, Inc.. 1575 Eye St NW, 4th Floor, Washington, DC 20005. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to [email protected]. You can unsubscribe or change which newsletters you receive anytime. See our full privacy policy.